UAE Bioinformatics Market Analysis Report 2022 to 2030

UAE Bioinformatics Market Analysis

$ 3999

UAE Bioinformatics market is projected to grow from $76.75 Mn in 2022 to $275.08 Mn by 2030, registering a CAGR of 1.30% during the forecast period of 2022-30. The main factors driving the growth are government initiatives, advances in technology, and an increasing demand for personalized medicine. The market is segmented by technology and by application. Some of the major players include G42 Healthcare (ARE), Neo-Science (ARE), Agilent Technologies, IBM Life Sciences, and QIAGEN.

ID: IN10AEHS001 CATEGORY: Healthcare Services GEOGRAPHY: UAE AUTHOR: Neha Davda

Buy Now

UAE Bioinformatics Market Executive Summary

UAE Bioinformatics market is projected to grow from $76.75 Mn in 2022 to $275.08 Mn by 2030, registering a CAGR of 1.30% during the forecast period of 2022-30. In 2019, national healthcare spending in the UAE as a percentage of GDP reached 4.28% from 4.15% in 2018. The UAE government has made it a top priority to build a top-notch healthcare infrastructure, and as a result, the industry has developed and grown tremendously over the past few years.

The study of biology and information technology are combined in the discipline of bioinformatics. Data generation, data warehousing, data mining, data management, and other techniques are used in bioinformatics. Bioinformatics software and tools are used as integrated solutions to provide statistical techniques and data processing algorithms for applications including next-generation sequencing, modeling of genomic and proteomic structure, and three-dimensional drug discovery. The bioinformatics market in the Middle-Eastern region is still in its nascent stages. However, UAE is one of the leading countries in the Middle-Eastern bioinformatics market.

uae bioinformatics market analysis

Market Dynamics

Market Growth Drivers

The UAE government has been making investments in the creation of bioinformatics resources and infrastructure, such as the Dubai Genome Center and the Abu Dhabi Advanced Research Center (ADARC), a molecular diagnostics company. This government support, advances in technology and an increasing demand for personalized medicine are expected to drive the bioinformatics market in UAE.

Market Restraints

The factors that are limiting the growth of the market are limited awareness about the potential benefits of bioinformatics and the shortage of skilled workforce in this field which makes it challenging for companies to adapt or implement new applications or technologies.

Competitive Landscape

Key Players

G42 Healthcare (ARE)
Neo-Science (ARE)
Agilent Technologies
IBM Life Sciences
QIAGEN

Notable Recent Deals

November 2022: The MOU between G42 Healthcare and Asa Ren aims to create and improve genomic sequencing, bioinformatics capabilities, and digital health solutions to support the Indonesian Government's National Genomics Initiatives and the digitization of the healthcare sector.

January 2023: The acquisition of Verogen by QIAGEN with $150 Mn was made to strengthen the company's position as a leader in the field of human identification and forensics, which is backed by process automation, genetic testing analysis, and sample preparation. Verogen and Illumina MiSeq FGx, NGS-based panels, and GEDmatch bioinformatics solutions would be supplied beginning in 2021, according to the deal.

Healthcare Policies and Regulatory Landscape

In the United Arab Emirates (UAE), the regulatory environment for the bioinformatics industry is still comparatively new and developing. Controlling and authorizing medical devices is within the purview of the Ministry of Health and Prevention (MOHAP). In the emirate of Dubai, the Dubai Health Authority (DHA) is responsible for overseeing the regulation of healthcare technology, including bioinformatics. Additionally, the UAE offers a variety of free trade zones that provide enterprises with laxer restrictions and incentives, including Dubai Silicon Oasis and Abu Dhabi Global Market. Furthermore, the UAE has put in place laws governing data security and privacy, including the Federal Law No. 2 of 2019 on Data Protection and the Cybercrime Law, which can be applicable to bioinformatics businesses that deal with genetically personal data.

Reimbursement Scenario

In UAE, reimbursement policies are set by individual insurance firms as well as government-funded healthcare providers. The cost of some genetic testing and other bioinformatics services is typically covered by these policies, but the precise tests and services that are covered, as well as the amount of the reimbursement, can change. The Ministry of Health and Prevention (MOHAP) in the UAE establishes the norm for medical operations, including the price of genetic tests. The MOHAP also controls medical procedure costs in the private sector; these costs require the Ministry of Health approval.

1. Executive Summary
1.1 Service Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Healthcare Services Market in Country
1.6 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Market Size (With Excel and Methodology)
2.2 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Services
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Bioinformatics Market Segmentation

By Technology (Revenue, USD Billion):

Knowledge Management Tools
Bioinformatics Platforms
Bioinformatics Services

By Application (Revenue, USD Billion):

Metabolomics
Molecular phylogenetics
Transcriptomics
Chemoinformatic & drug design
Genomics
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.